The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Canopy Growth, Cheniere, CSX, Johnson & Johnson, Motorola, Slack, Tilray and VMware.
Many of the technology advances being made by the world's top tech, industrial and other companies have only just started to see revenues. That is why we are focusing on an ETF theme around robotics,...
The top analyst upgrades, downgrades and initiations seen on Thursday included AbbVie, Agilent Technologies, Albermarle, Apple, Boeing, Cheniere Energy, First Solar, HCA, LabCorp, Lumber Liquidators...
Think you understand what's going on? You haven't got a clue, according to ZeroHedge.
  Stocks were hammered on Monday and were indicated to open handily lower on Tuesday due to another disappointment from Boeing and due to poor retail stock earnings reactions. Investors have...
Thursday was a flat day for the broad U.S. markets, although each one of the major averages was fairly positive at one point in the day. Crude oil made another solid gain in the session putting it...
The top analyst upgrades, downgrades and other research calls from Tuesday include Albermarle, BB&T, Cheniere Energy Partners, Chesapeake Energy, Kinder Morgan, Red Hat and Roku.
Americans are expected to spend $351 billion in 2018 on items like smart speakers, virtual reality headsets, smartphones and other high-tech devices.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
U.S. households currently own 238 million smartphones, a year-over-year increase of 27 million, according to a new report from the Consumer Technology Association.
The increasing use of smartphones for shopping has had a drastic impact on the consumer’s path to purchase, according to recent data.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Cisco, Cree, Exxon Mobil, Hewlett Packard Enterprise, Urban Outfitters, Valeant Pharmaceuticals, Western Digital.
Audentes Therapeutics expects to price its 5 million shares in the range of $14 to $16, for an initial public offering valued up to $92 million.
Audentes Therapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Clovis Oncology, CSC, Norfolk Southern, Sprint, Square and Western Digital.